Recent Investment Analysts’ Ratings Changes for Evommune (EVMN)

Several analysts have recently updated their ratings and price targets for Evommune (NYSE: EVMN):

• 1/7/2026 – Evommune is now covered by analysts at Raymond James Financial, Inc.. They set a “strong-buy” rating and a $40.00 price target on the stock.
• 1/7/2026 – Evommune is now covered by analysts at Raymond James Financial, Inc.. They set a “strong-buy” rating and a $40.00 price target on the stock.
• 1/7/2026 – Evommune was upgraded by analysts at The Goldman Sachs Group, Inc. to a “buy” rating.
• 1/6/2026 – Evommune is now covered by analysts at HC Wainwright. They set a “buy” rating and a $35.00 price target on the stock.
• 1/6/2026 – Evommune is now covered by analysts at HC Wainwright. They set a “buy” rating and a $35.00 price target on the stock.
• 12/14/2025 – Evommune was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/6/2025 – Evommune was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/2/2025 – Evommune was upgraded by analysts at Zacks Research to a “hold” rating.
• 12/1/2025 – Evommune is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 12/1/2025 – Evommune is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $40.00 price target on the stock.
• 12/1/2025 – Evommune is now covered by analysts at William Blair. They set an “outperform” rating on the stock.
• 12/1/2025 – Evommune is now covered by analysts at Morgan Stanley. They set an “overweight” rating and a $36.00 price target on the stock.
• 12/1/2025 – Evommune is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $40.00 price target on the stock.
• 12/1/2025 – Evommune was upgraded by analysts at Leerink Partners to a “strong-buy” rating.
• 12/1/2025 – Evommune is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $42.00 price target on the stock.

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.